Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$5.41
+11.8%
$3.13
$1.47
$15.49
$132.14M2.836.43 million shs992,970 shs
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$8.61
-1.5%
$9.20
$5.22
$14.44
$739.98M0.831.35 million shs804,520 shs
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
$9.50
$9.48
$2.32
$9.67
$928.85M1.631.12 million shsN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.98
+3.5%
$5.32
$4.16
$14.45
$830.72M1.271.54 million shs1.41 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
+11.78%-9.98%+87.85%+50.28%-50.59%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-1.49%-4.12%+2.01%-29.02%+59.74%
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
0.00%0.00%0.00%0.00%+280.00%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
+3.46%+3.46%+13.69%+5.84%-20.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$5.41
+11.8%
$3.13
$1.47
$15.49
$132.14M2.836.43 million shs992,970 shs
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$8.61
-1.5%
$9.20
$5.22
$14.44
$739.98M0.831.35 million shs804,520 shs
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
$9.50
$9.48
$2.32
$9.67
$928.85M1.631.12 million shsN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.98
+3.5%
$5.32
$4.16
$14.45
$830.72M1.271.54 million shs1.41 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
+11.78%-9.98%+87.85%+50.28%-50.59%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-1.49%-4.12%+2.01%-29.02%+59.74%
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
0.00%0.00%0.00%0.00%+280.00%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
+3.46%+3.46%+13.69%+5.84%-20.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
2.60
Moderate Buy$18.25237.34% Upside
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
2.25
Hold$44.00411.03% Upside
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
2.00
Hold$9.50N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.73
Moderate Buy$17.30189.30% Upside

Current Analyst Ratings Breakdown

Latest ARTV, VIR, AVXL, and PSTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/24/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/24/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
Jones Trading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
10/17/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$18.00 ➝ $23.00
10/17/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$18.00
10/14/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/7/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$42.00
10/1/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$46.00
9/27/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$250K528.67N/AN/A$7.68 per share0.70
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/A$1.42 per shareN/A
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
$150.86M6.16N/AN/A$1.08 per share8.80
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$14.39M57.72N/AN/A$8.35 per share0.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$65.37M-$2.62N/AN/AN/AN/A-42.60%-37.76%11/11/2025 (Estimated)
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%11/28/2025 (Estimated)
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
-$123.43M-$0.63N/AN/AN/A-40.28%-72.26%-21.53%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%11/5/2025 (Confirmed)

Latest ARTV, VIR, AVXL, and PSTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2025Q3 2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.90N/AN/AN/AN/AN/A
11/5/2025Q3 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.70N/AN/AN/A$1.98 millionN/A
8/12/2025Q3 2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$0.13-$0.16-$0.03-$0.16N/AN/A
8/6/2025Q2 2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.84-$0.87-$0.03-$0.87N/AN/A
8/6/2025Q2 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/AN/A
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
13.84
13.84
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/A
8.93
8.93
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
0.68
3.20
3.20
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
7.01
7.01

Institutional Ownership

CompanyInstitutional Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
31.55%
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
46.87%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
21.40%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
11.40%
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
2.90%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
8124.43 million19.20 millionN/A
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
4085.89 million76.10 millionOptionable
Poseida Therapeutics, Inc. stock logo
PSTX
Poseida Therapeutics
26097.77 million94.94 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.92 million116.69 millionOptionable

Recent News About These Companies

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Thursday
Vir Biotechnology (VIR) Gets a Buy from H.C. Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$5.41 +0.57 (+11.78%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$5.20 -0.21 (-3.88%)
As of 10/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Anavex Life Sciences stock logo

Anavex Life Sciences NASDAQ:AVXL

$8.61 -0.13 (-1.49%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$8.71 +0.10 (+1.11%)
As of 10/24/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Poseida Therapeutics stock logo

Poseida Therapeutics NASDAQ:PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$5.98 +0.20 (+3.46%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$5.98 -0.01 (-0.08%)
As of 10/24/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.